These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 34349762)

  • 1. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
    Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
    Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
    Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
    Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
    Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A promising target for breast cancer: B7-H3.
    Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
    BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
    Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
    Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
    Front Immunol; 2021; 12():757047. PubMed ID: 34675936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 immunoregulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3-mediated tumor immunology: Friend or foe?
    Wang L; Kang FB; Shan BE
    Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer.
    Ding J; Sun Y; Sulaiman Z; Li C; Cheng Z; Liu S
    Int J Gen Med; 2023; 16():367-391. PubMed ID: 36756390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
    Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
    Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 and its role in bone cancers.
    He L; Li Z
    Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.